首页> 美国卫生研究院文献>World Journal of Gastroenterology >Preoperative risk factor analysis in orthotopic liver transplant-ation with pretransplant artificial liver support therapy
【2h】

Preoperative risk factor analysis in orthotopic liver transplant-ation with pretransplant artificial liver support therapy

机译:移植前人工肝支持治疗原位肝移植术前危险因素分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

AIM: To assess the value of pre-transplant artificial liver support in reducing the pre-operative risk factors relating to early mortality after orthotopic liver transplantation (OLT).METHODS: Fifty adult patients with various stages and various etiologies undergoing OLT procedures were treated with molecular adsorbent recycling system (MARS) as preoperative liver support therapy. The study included two parts, the first one is to evaluate the medical effectiveness of single MARS treatment with some clinical and laboratory parameters, which were supposed to be the therapeutical pre-transplant risk factors, the second part is to study the patients undergoing OLT using the regression analysis on preoperative risk factors relating to early mortality (30 d) after OLT.RESULTS: In the 50 patients, the statistically significant improvement in the biochemical parameters was observed (pre-treatment and post-treatment). Eight patients avoided the scheduled Ltx due to significant relief of clinical condition or recovery of failing liver function, 8 patients died, 34 patients were successfully bridged to Ltx, the immediate outcome of this 34 patients within 30d observation was: 28 kept alive and 6 patients died.CONCLUSION: Pre-operative SOFA, level of creatinine, INR, TNF-α, IL-10 are the main preoperative risk factors that cause early death after operation, MARS treatment before transplantion can relieve these factors significantly.
机译:目的:评估移植前人工肝支持在降低与原位肝移植(OLT)后早期死亡相关的术前危险因素中的价值。方法:对50例接受OLT手术的不同阶段和病因的成年患者进行了治疗。分子吸附剂回收系统(MARS)作为术前肝支持疗法。该研究包括两部分,第一部分是通过一些临床和实验室参数来评估单一MARS治疗的医学有效性,这些参数被认为是治疗前的移植危险因素;第二部分是使用以下方法研究接受OLT治疗的患者结果:50例患者的生化指标(治疗前和治疗后)均有统计学意义的改善。由于临床状况的明显缓解或肝功能衰竭的恢复,有8例患者避免了预定的Ltx,8例患者死亡,34例成功桥接至Ltx,这34例患者在30天内观察到的直接结果是:28例存活,6例患者结论:术前SOFA,肌酐,INR,TNF-α,IL-10水平是导致术后早期死亡的主要术前危险因素,移植前进行MARS治疗可明显缓解这些因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号